At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

The Advisory Committee on Immunization Practices convened to make expanded vaccine recommendations amidst CDC leadership changes.